ICICI Prudential Nifty Pharma Index Fund-Growth
The fund is rated 4 stars. Considered together, the fund's movement relative to its index and annual fee of 1.18% place it ahead of most similar funds.
This index fund/ETF has a beta of 0.936%, and an expense ratio of 1.18%, giving it a 4.0 star rating, based on the principle that lower values of |1-beta| and expense ratio result in higher ratings.
Our score weighs long-term performance, risk and consistency — not just past returns.
Returns
As of 7 Oct 2026
Risk ratios
As of 30 Sep 2026
Portfolio
As of 31 Aug 2026
Market-cap split
Sector allocation
Holdings (21)
| Holding | % of fund | Value | Shares |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 20.76% | ₹32.57 Cr | 1,64,106 |
| Divi's Laboratories Ltd. | 11.88% | ₹18.64 Cr | 19,688 |
| Cipla Ltd. | 7.83% | ₹12.29 Cr | 87,200 |
| Laurus Labs Ltd. | 7.36% | ₹11.55 Cr | 60,292 |
| Torrent Pharmaceuticals Ltd. | 7.34% | ₹11.51 Cr | 22,724 |
| Dr. Reddy's Laboratories Ltd. | 6.95% | ₹10.91 Cr | 94,471 |
| Lupin Ltd. | 5.25% | ₹8.24 Cr | 37,631 |
| Aurobindo Pharma Ltd. | 4.69% | ₹7.36 Cr | 42,891 |
| Glenmark Pharmaceuticals Ltd. | 3.69% | ₹5.78 Cr | 23,325 |
| Alkem Laboratories Ltd. | 3.08% | ₹4.83 Cr | 9,056 |
Fund details
Long term wealth creation solution. An index fund that seeks to track returns by investing in a basket of Nifty Pharma Index stocks and aims to achieve returns of the stated index, subject to tracking error.
The Scheme seeks to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index